Eli Lilly will expand its manufacturing site in Suzhou, China, to produce two recently approved drugs for tirzepatide in China—one for Type 2 diabetes and the other for obesity, along with other pipeline medicines.

The company has earmarked a reported $200 million for the upgrade, and comes as Lilly focuses investments in manufacturing to meet the increasing demand for its blood sugar-modulating products Mounjaro, for diabetes, and Zepbound, for obesity. Lilly recently announced that it will invest $1.8 billion to expand production capacity at two plants in Ireland, as well as a $2.5 billion factory under construction in Alzey, Germany, which is expected to begin production in 2027.